Tuesday , September 28 2021

▷ Californian research team publishes promising results …



Santa Clara, CA (PRNewswire / -) – Dr. Ing. Team of researchers. The Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine is intended for specific enzymes called metoproteinase (MMP), which are responsible for tumor growth, metastatic and vascular formation in the tumors (angiogenesis). Dr. A study group showed that tested mice vaccinated with peptides containing specific MMP-2 and MMP-9 sequences and then infected with melanoma cancer cells reduced tumor by approximately 76% compared to unvaccinated Animals from the control group. Significantly, some vaccinated animals did not have cancer at all.

The study was published in October 2018 in the online cellular medicine and nature journal.

Cancer is still the second largest epidemic in the world. This disease causes more than 7 million people each year. This new therapist approach can significantly alter these statistics. Compared to monoclonal antibodies (Mabs) or biologically-like molecules that have recently been developed as anticancer agents, the anti-MMP vaccine method promises a more effective and affordable worldwide fight against the disease. While Mab / biosimilar is targeting a specific type of cancer, the anti-MMP vaccine can fight all forms of cancer. Another advantage is that, unlike Mab / Biosimilars, where it is usually injected once or twice a month, an anti-MMP vaccine should only be injected once and after several years of vaccination it is necessary.

Anti-MMP vaccine, if successfully completed, can be offered at a reasonable cost to patients from national or international healthcare facilities.

To make this valuable technology accessible to most patients and countries around the world, the research institute Dr. Mr Patent has filed a patent application in many countries. The Institute requires public and public research institutions and other non-profit institutions to develop this promising technology with them, with a view to successfully treating, preventing and preventing cancer, in the first place.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

US Patent No. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Press contact:

Dr. Alexandra Niedzwiecki
CEO
Dr. Wheel research institute
E-mail: [email protected]

Original content: Dr. med The Matter Research Institute, transmitted with novelties aktuell


Source link